The effect of modafinil on daytime sleepiness, neurobehavioural performance and quality of life in obstructive sleep apnea patients
This study will establish if modafinil can improve neurobehavioural and quality of life outcomes in patients with obstructive sleep apnea.
Obstructive Sleep Apnea (OSA) is an important cause of impaired quality of life (QOL), neurobehavioural (attention, sleepiness, cognition) and cardiovascular morbidity and mortality. Current scientifically established treatments for OSA (Continuous Positive Airway Pressure, CPAP and oral appliances) are accepted and used long term by only ~50% of patients seeking medical attention for OSA related symptoms. There is a strong need for alternative approaches in mechanical treatment-intolerant OSA patients. In this project, we propose to investigate whether administration of the wakefulness promoter, modafinil, will improve neurobehavioural and QOL outcomes.
Want to find out more?
Contact Research Expert to find out more about participating in this opportunity.
Browse for other opportunities within the Camperdown - Woolcock Institute of Medical Research .
The opportunity ID for this research opportunity is: 1122
Other opportunities with Professor Ron Grunstein
- Melatonin as a treatment for Delayed Sleep Phase Disorder
- Chronotherapy for hypertension in obstructive sleep apnea
- Creatine therapy to improve neurobehavioural function in obstructive sleep apnea
- Which sleep apnea patients have problems with alertness and attention?
- Developing a psychoeducation program to improve sleep-wake disturbances in Parkinson’s Disease
Other opportunities with Associate Professor Peter Liu